TARLATAMAB

Information current as at: 1 July 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Imdelltra®
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
AMGEN AUSTRALIA PTY LIMITED
Condition/indication:
(therapeutic use)
  • Extensive-stage small cell lung cancer
Listing requested:
Please see meeting agenda for more information
Funding program:
PBS Section 100 (Efficient Funding of Chemotherapy Program)
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Other business (Matters arising/Matters outstanding)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
May 2026 PBAC meeting
Opportunity for consumer comment:
Open 19/11/2025 and close 21/01/2026 (see PBS Website)
PBAC meeting:
Held on 08/05/2026
PBAC outcome published:
Advice Provided (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
Not yet available
Case ID
a1183
Page last updated
30 June 2026
Return to the Medicine Status Listing
v.9.19